Sarepta Hires Ex-Allergan Leader with M&A history as CEO

Source: FierceBiotech

Thursday, June 29, 2017 | Management/Leadership


Doug Ingram has become the latest person to take a turn as Sarepta Therapeutics CEO. The former Allergan president is set to replace Ed Kaye, M.D., putting him in charge of turning Sarepta into a successful commercial-stage biotech with a pipeline of promising programs. Ingram arrives at Sarepta fresh from success in his last stint at the helm of a biotech. As CEO of Chase Pharmaceuticals, Ingram guided the biotech through a phase 2 Alzheimer’s disease trial and on to a takeover by Allergan. Brent Saunders’ Allergan paid $125 million upfront to make Chase its latest acquisition.

Open in New Window

Comments

You must be logged in to leave a comment.